Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Astrocytoma 3Recurrence 2Prostatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Intestine Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neurofibroma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neurilemmoma 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Mesothelioma, Malignant 1

Interventions

Temozolomide 4Surgical Procedures, Operative 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Gadolinium DTPA 2Filgrastim 2Erlotinib Hydrochloride 2Congresses as Topic 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2vitespin 1sargramostim 1picropodophyllin 1marizomib 1imetelstat 1gadobutrol 1gadobenic acid 1fluorodopa F 18 1bempegaldesleukin 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Transurethral Resection of Bladder 1Topotecan 1Thiotepa 1Ritonavir 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Perfusion Magnetic Resonance Imaging 1O(6)-benzylguanine 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ependymoma × antineoplaston AS 2-1 × Clear all
NCT00003479 2022-02-23

Antineoplaston Therapy in Treating Patients With Ependymoma

Burzynski Research Institute

Phase 2 Terminated
9 enrolled 6 charts

Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡